News | August 19, 2025
Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Revenue increased 11.4 per cent to Rs. 8,545 crore
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
A triple-action Formula for comprehensive respiratory relief
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Subscribe To Our Newsletter & Stay Updated
